Advancing the pivotal Phase III MAVERIC trial evaluating the efficacy, safety, and tolerability of CardiolRx™ (oral cannabidiol solution) in patients with recurrent pericarditis.

Expected impact: Supports a planned New Drug Application (NDA) with the U.S. FDA to address a significant unmet need in the recurrent pericarditis market.

Developing CRD-38, a novel subcutaneously administered formulation of cannabidiol, designed to target the underlying inflammation and fibrosis driving heart failure.

Expected impact: Establishes a second major therapeutic pipeline asset targeting the broader heart failure market, which has high mortality rates and massive associated healthcare costs.

Broadening and securing global patent protection for lead drug candidates CardiolRx™ and CRD-38 across multiple cardiac indications.

Expected impact: Provides long-term market exclusivity and robust IP protection covering heart failure, myocarditis, pericarditis, and other inflammatory cardiac conditions.